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were excluded from the analysis. Only Deep Venous
Thrombosis and Pulmonary embolism were included in the
analysis.
Results: Among the ﬁnal 34 studies with adequate data for
analysis, N was 8353. 522 patients developed DVT or PE in
the cohort giving an incident rate of 6.12%. Quality appraisal
was performed for clinical trials using the Cochrane Risk of
Bias tool, which indicated poor quality of reporting in
majority of trials with possibility of introducing bias. A
meta-regression model could not be constructed due to
non-uniform reporting of the outcome of interest and
because of signiﬁcant methodologic variation between the
studies. Among the patients receiving immunomodulatory
(IMiD) therapy post-HSCT (n¼703), 22.7% developed VTE.
Chronic graft versus host disease did not affect the rates of
VTE; although most of the studies in the ﬁnal cohort did not
report the cGVHD incidence. VTE incidence in autologous
HSCT and allogeneic HSCT was 9.43% (196/2078) and 4.61%
(180/3902) respectively [data missing or not reported for
rest].
Conclusions: VTE can be life-threatening late complication
of HSCT with substantial number of patients developing PE
or DVT post HSCT. Results of our study with a large sample
size indicate a substantial risk of VTE with IMiD usage in
HSCT patients. Further studies from large database would
be helpful in deciphering the associations of VTE with
GVHD and establishing guidelines for prophylaxis and
management.64
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Background: Ocular involvement occurs in more than half of
patients with chronic graft-versus-host disease (GVHD),
compromising both quality of life and function. Ocular GVHD
can be refractory to treatment once dry eye syndrome is
established. A bandage contact lens (BCL) is a widely
available, disposable, soft contact lens used for the treatmentof a diseased or injured cornea. We performed a phase II trial
of BCLs for patients with ocular GVHD.
Methods: Eligibility criteria included adult patients with
moderate to severe ocular GVHD according to NIH consensus
criteria. BCLs were replaced every 2-4 weeks. Patients were
instructed to use daily antibiotic eye drops to prevent ocular
infection. Patients completed standardized symptom
questionnaires at enrollment and at 2 weeks, 4 weeks and 3
months after placement of BCLs. The primary endpoint was
symptom improvement by the Lee eye subscale after 2weeks
of therapy. Secondary endpoints included improvement in
ocular surface disease index (OSDI), 11-point eye
symptom rating and ophthalmologic assessments during 3
months of therapy. For patient-reported measures, higher
scores indicate worse symptoms. Measures at follow-up
assessments were compared with those at enrollment by
paired t-test. Patients gave written consent to participate in
the study and the Institutional Review Board approved the
study.
Results: Nineteen patients participated in the study from
August 2012 to August 2014. Median agewas 55 years (range,
32-75), and median time from transplantation to enrollment
was 36.5 months (range, 8-157 months). Fourteen patients
had moderate ocular GVHD and 5 had severe ocular GVHD at
enrollment. The mean Lee eye subscale score at enrollment
was 75, and the score improved signiﬁcantly at 2 weeks
(mean 63; p¼0.02) and thereafter (Figure). The mean OSDI
score at enrollment was 55.5, and the score improved
signiﬁcantly at 2 weeks (mean 37.1; p¼0.002) and
thereafter. According to the Lee eye subscale, 44% showed
clinically meaningful improvement at 2 weeks, 53% at 4
weeks and 54% at 3 months. According to ophthalmologic
examination at 2 weeks, ocular GVHD showed 89%
improvement, 5% stability and 5% worsening. At 2 weeks,
one patient stopped BCLs due to discomfort, and another
patient did not wear one lens after it fell out. At 3 months,
2 patients stopped using BCLs after eye symptoms had
sufﬁciently improved, and another patient stopped
using BCL due to blurred vision. The most frequent
adverse events within 3 months after BCL placement
included foreign body sensation (74%), swollen eyelids
(26%) and excessive tearing (11%). No ocular infection or
other corneal complications were documented during the
3 months.
Conclusion: BCLs are a safe, tolerable and effective
treatment that improves symptoms of moderate to severe
ocular GVHD in approximately 50% of patients. This study
was registered at www.clinicaltrials.gov as NCT01616056.
